What does Sarepta Therapeutics do?
Sarepta Therapeutics, Inc. is a Nasdaq-listed commercial biopharmaceutical company focused on precision genetic medicines for rare diseases. Duchenne muscular dystrophy, or DMD, provides the commercial base. Unlike a diversified pharmaceutical group, Sarepta depends on four high-value therapies, specialized treatment infrastructure, payer authorization, and complex manufacturing.
| Company dimension | Sarepta profile | Why it matters |
|---|---|---|
| Commercial portfolio | EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS | Four approved DMD therapies reduce single-product dependence. |
| Technology mix | Phosphorodiamidate morpholino oligomers, or PMOs, plus AAV gene therapy | Recurring infusions and one-time gene therapy have different economics. |
| Primary customers | Specialty distributors, treatment centers, hospitals, payers, and government programs | Reimbursement execution is as important as scientific differentiation. |
| Geographic model | Direct U.S. commercialization; Roche-led ELEVIDYS commercialization outside the United States | The alliance extends reach while sharing economics and execution. |
| Reporting structure | One reportable segment | Product and collaboration economics must be reconstructed from detailed disclosures. |
Who does the company serve?
DMD is a progressive neuromuscular disease caused by dystrophin-gene mutations. Sarepta's PMO medicines address mutations amenable to skipping exon 51, 53, or 45. ELEVIDYS uses an AAV vector to deliver a shortened dystrophin construct. The official product portfolio therefore spans mutation-specific chronic therapy and a broader one-time gene-therapy approach.
Why does Sarepta matter in rare disease?
Sarepta helped turn DMD from a supportive-care market into one with multiple genetically targeted medicines. Its position brings commercial advantages but also exposes the company to evidence standards, safety, small patient populations, and specialized-center capacity.
How does Sarepta Therapeutics make money?
Sarepta earns product sales, collaboration and milestone revenue, and partner-related manufacturing revenue. Product revenue best reflects commercial demand; collaboration revenue can be valuable but episodic, making a quarter appear more profitable than the core business.
How do recurring PMO sales differ from one-time gene therapy?
PMO revenue depends on patient starts, persistence, reimbursement, and competition by exon. ELEVIDYS is administered once, so revenue is more sensitive to the untreated eligible population, center capacity, payer approvals, and safety pauses.
What does the Roche relationship contribute?
Under the Roche partnership, Sarepta retained U.S. rights to ELEVIDYS while Roche received exclusive commercial rights outside the United States. Sarepta participates in manufacturing and development economics, creating milestones, manufacturing revenue, and potential royalties that may not track end-market demand.
| Revenue source | Q1 2026 amount | Economic pattern | Primary driver |
|---|---|---|---|
| PMO product sales | $228.6M | Recurring infusions | Patient starts, persistence, mutation eligibility, and payer access |
| ELEVIDYS product sales | $102.0M | One-time administration | Current label, center readiness, safety confidence, and reimbursement |
| Collaboration and other revenue | $400.3M | Milestones, deferred-revenue recognition, and manufacturing activity | Partner decisions, regulatory milestones, and contract terms |
What does Sarepta's latest quarter show?
The first-quarter 2026 results show strong reported earnings but weaker commercial momentum. Total revenue was $730.8M and nearly flat year over year, while net product revenue fell to $330.5M from $611.5M because collaboration revenue offset the decline.
Which Q1 2026 numbers matter most?
| Metric | Q1 2026 | Interpretation |
|---|---|---|
| Total revenue | $730.8M | Collaboration revenue offset lower product sales. |
| Net product revenue | $330.5M | ELEVIDYS drove the commercial decline. |
| Collaboration and other revenue | $400.3M | Included partner recognition and a Japan milestone. |
| R&D expense | $154.0M | Restructuring reduced the expense base. |
| GAAP net income | $331.0M | Collaboration accounting amplified reported profit. |
| Diluted EPS | $2.88 | EPS overstates recurring commercial economics. |
| Operating cash flow | $(202.7)M | Cash use improved but remained negative. |
Why should reported profit be normalized?
Q1 2026 collaboration revenue included $365.0M tied to Roche's declined option and related rights, plus a $40.0M Japan milestone. These are real economics but not repeatable quarterly product sales. The Q1 2026 Form 10-Q is most useful when revenue categories and cash flow are separated.
ELEVIDYS safety and PMO durability define the portfolio
Sarepta's portfolio is a two-part story: recurring PMO revenue across three mutation groups and one-time ELEVIDYS revenue with greater safety, regulatory, and manufacturing risk. A label change can therefore alter companywide growth and operating leverage.
| Therapy | Commercial role | Regulatory or clinical feature | Key economic sensitivity |
|---|---|---|---|
| EXONDYS 51 | Recurring PMO therapy for exon 51-amenable DMD | Accelerated-approval franchise anchor | Persistence, payer access, and competitive exon-skipping data |
| VYONDYS 53 | Recurring PMO therapy for exon 53-amenable DMD | Supplemental application submitted in April 2026 seeking traditional approval | Confirmatory evidence and mutation-specific competition |
| AMONDYS 45 | Recurring PMO therapy for exon 45-amenable DMD | Supplemental application submitted in April 2026 seeking traditional approval | Conversion from accelerated approval and treated-patient growth |
| ELEVIDYS | One-time AAV gene therapy | Current U.S. indication is ambulatory patients age four and older with a confirmed DMD mutation | Safety confidence, treatment-center capacity, reimbursement, and label scope |
Why does the current ELEVIDYS label matter?
The current FDA product page limits the U.S. indication to ambulatory patients age four and older. In 2025, reports of fatal acute liver failure in non-ambulatory patients led the FDA to require a boxed warning and revised use. The FDA safety action also required intensive monitoring and a postmarketing study of about 200 patients followed for at least 12 months.
Why do PMO products provide financial ballast?
In Q1 2026, PMO revenue was $228.6M and ELEVIDYS revenue was $102.0M. The mix explains why the older franchise remains strategically important. FY2026 net product revenue guidance of $1.2B to $1.4B implies stabilization, not a return to the former ELEVIDYS run rate.
Which turning points shaped Sarepta's business?
Sarepta's history is a sequence of platform, regulatory, and capital-allocation decisions that shifted the balance between PMO revenue, gene-therapy upside, partner economics, and development risk.
What events still define the company today?
-
2016EXONDYS 51 received accelerated approval, converting Sarepta from a development-stage company into a commercial rare-disease business.
-
2019The Roche alliance assigned ex-U.S. ELEVIDYS commercialization to a global partner, adding milestones and manufacturing economics while preserving Sarepta's U.S. opportunity.
-
2019–2021VYONDYS 53 and AMONDYS 45 expanded the PMO franchise across additional mutation groups, reducing dependence on EXONDYS 51 alone.
-
2023ELEVIDYS received its first U.S. approval, establishing the first commercial gene-therapy platform within Sarepta's DMD franchise.
-
2024The ELEVIDYS indication expanded, accelerating treatment-center adoption and making gene therapy nearly half of FY2025 product revenue.
-
2025Safety events narrowed the commercial opportunity. Sarepta then announced a 36% workforce reduction, about 500 positions, and targeted roughly $400M in annual cost savings while prioritizing siRNA programs.
-
2026Japan's commercial launch generated a $40.0M milestone, early SRP-1001 and SRP-1003 data supported the siRNA strategy, and ENDEAVOR Cohort 8 began testing a risk-mitigation approach in about 25 non-ambulatory participants.
Sarepta repeatedly used one asset class to fund the next: PMOs supported gene therapy, Roche shared global execution, and the 2025 restructuring concentrated resources. This explains both resilience and sensitivity to clinical or regulatory shocks.
What gives Sarepta a competitive advantage?
Sarepta's moat is an integrated DMD operating system: genetic testing, patient identification, specialist relationships, payer experience, treatment-center support, pharmacovigilance, manufacturing know-how, and longitudinal evidence. A new entrant cannot reproduce this quickly.
The infrastructure also improves development feedback: treated-patient data, physician relationships, and assay experience can inform trial design and launch planning. That learning loop is unusually valuable in rare disease, where small samples and scarce specialist capacity make execution experience disproportionately important.
Where is the moat strongest?
These are analytical ratings as of Q1 2026, not company guidance. Regulatory durability and diversification score lower because ELEVIDYS safety remains central and siRNA programs remain early.
Where is the moat fragile?
Specialization also creates concentration. ELEVIDYS depends on one source for drug substance and product manufacturing, while two customers represented 39% and 20% of Q1 2026 product revenue. Payer delays, new safety findings, or stronger competitor data can weaken the franchise.
Who are Sarepta's main competitors?
Competition is modality-specific: exon-skipping drugs, alternative gene therapies, other DMD medicines, gene editing, and RNA-targeted platforms. This broad rivalry raises R&D requirements and expands physician and payer choice.
| Competitive field | Selected competitors disclosed by Sarepta | Basis of competition | Sarepta's position |
|---|---|---|---|
| Exon skipping | Nippon Shinyaku, Wave, Dyne, Novartis/Avidity, Entrada, and others | Dystrophin expression, dosing convenience, safety, and mutation coverage | First-mover commercial depth, offset by pressure for stronger functional evidence |
| DMD gene therapy | Solid/Ultragenyx, REGENXBIO, Genethon, and others | Functional benefit, durability, vector safety, manufacturing, and eligibility | Commercial lead, but current label and safety monitoring constrain the addressable market |
| Other DMD medicines | Santhera, Italfarmaco, Capricor/Nippon, Edgewise, and others | Function, disease progression, combination potential, and payer value | Genetic targeting differentiates Sarepta, but alternatives can compete for the same patients |
| siRNA and RNA-targeted platforms | Novartis/Avidity, Dyne, Vertex, Wave, Entrada, Biohaven, and others | Tissue delivery, target engagement, dosing, tolerability, and clinical translation | Early clinical signals are encouraging, but platform leadership is not yet established |
Why is rivalry unusually intense in genetic medicine?
Barriers are high because trials require rare-patient recruitment, specialized assays, regulatory engagement, and complex manufacturing. Rivalry remains intense. Payers and treatment centers influence access and throughput, while ELEVIDYS manufacturing concentration raises supplier power. Sarepta's capabilities do not eliminate substitution risk or the need for superior evidence.
How financially strong is Sarepta Therapeutics?
Sarepta's liquidity must be assessed beside debt, inventory, development commitments, and volatile collaboration cash flows. At March 31, 2026, cash, restricted cash, and investments were $748.3M versus $838.2M of long-term debt. Inventory was also substantial.
What do liquidity and debt show?
| Balance-sheet or cash-flow item | Period | Amount | Analytical implication |
|---|---|---|---|
| Cash, restricted cash, and investments | March 31, 2026 | $748.3M | Provides runway but is below debt. |
| Current and non-current inventory | March 31, 2026 | $1.176B | Demand forecasts and shelf-life management are important. |
| Long-term debt | March 31, 2026 | $838.2M | Convertible notes mature in 2027 and 2030. |
| Operating cash flow | Q1 2026 | $(202.7)M | Reported profit did not convert into cash. |
How should cash flow and capital allocation be read?
The FY2025 results and FY2025 Form 10-K reported $1.864B of product revenue, including $965.6M from PMOs and $898.7M from ELEVIDYS. Total R&D expense reached $1.522B, including a $583.6M up-front Arrowhead payment and $300.0M of milestones. Those charges explain why FY2025 revenue growth did not produce accounting profitability.
FY2026 non-GAAP R&D plus SG&A guidance of $800M to $900M tests whether restructuring can lower costs without weakening commercialization, safety monitoring, or siRNA development.
Who owns SRPT stock, and why does governance matter?
Sarepta has one-vote common stock rather than founder-style dual-class control. Ownership is institutionally influenced, while management retains meaningful exposure. The latest 2026 proxy statement used 105,571,146 shares outstanding on April 8, 2026.
Which holders have the most influence?
| Holder or group | Economic stake | Why it matters |
|---|---|---|
| BlackRock | 12.5% | Largest disclosed holder with meaningful voting influence. |
| AQR-affiliated entities | 7.7% | A second large external voting bloc. |
| State Street | 5.0% | Passive ownership emphasizes governance and disclosure. |
| Douglas Ingram, CEO | 2.5% | Direct and option-based CEO exposure. |
| Current directors and executive officers as a group | 6.9% | Meaningful exposure without voting control. |
What do incentives and board oversight signal?
The board has Audit, Compensation, Governance, and R&D committees. The CEO's 2025 equity design combined restricted stock units with an EBITDA-linked performance award, and the board reduced his target bonus opportunity after restructuring, signaling greater cost discipline.
What opportunities and risks could change Sarepta's outlook?
Upside depends on stabilizing ELEVIDYS, defending PMOs, converting accelerated approvals, expanding with Roche, and validating siRNA. Downside centers on safety, regulatory limits, commercial erosion, manufacturing dependence, and cash use.
Which forward indicators deserve the most attention?
Other risks include product liability, litigation, intellectual-property challenges, manufacturing deviations, and biomarkers that fail to predict benefit. A safety event can slow demand, strand inventory, reduce cash flow, and raise the pipeline discount rate.
What is the key takeaway from Sarepta Therapeutics analysis?
Sarepta is a concentrated rare-disease franchise with commercial scale, DMD infrastructure, volatile partner accounting, and a pipeline being rebuilt around siRNA. It must protect PMO cash flows and restore ELEVIDYS confidence while reducing spending.
Which variables matter most in a DCF?
A valuation should separate product demand from milestones, use product-specific probabilities, normalize one-time R&D charges, and model working capital. Q1 2026 reported profitability is not sustainable because collaboration revenue was unusual, while FY2025's loss was distorted by Arrowhead charges.
Terminal value deserves caution because exclusivity, safety surveillance, competition, and manufacturing concentration raise long-duration uncertainty. Near-term evidence will come from product stabilization, ELEVIDYS safety, PMO approval conversions, siRNA data, cash flow, and expense control.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.